Finnland - finnska - Fimea (Suomen lääkevirasto)

ceva-phylaxia veterinary biologicals co. ltd. - marek's disease virus, serotype 1, cvi-988 - injektiokonsentraatti ja liuotin, suspensiota varten - marekin tauti -rokote

Finnland - finnska - Fimea (Suomen lääkevirasto)

boehringer ingelheim animal health nordics a/s - permethrin, fipronil - paikallisvaleluliuos - fiproniili

Finnland - finnska - Fimea (Suomen lääkevirasto)

boehringer ingelheim animal health nordics a/s - permethrin, fipronil - paikallisvaleluliuos - fiproniili

Finnland - finnska - Fimea (Suomen lääkevirasto)

boehringer ingelheim animal health nordics a/s - permethrin, fipronil - paikallisvaleluliuos - fiproniili

Finnland - finnska - Fimea (Suomen lääkevirasto)

boehringer ingelheim animal health nordics a/s - permethrin, fipronil - paikallisvaleluliuos - fiproniili

Finnland - finnska - Fimea (Suomen lääkevirasto)

boehringer ingelheim animal health nordics a/s - permethrin, fipronil - paikallisvaleluliuos - fiproniili

Evrópusambandið - finnska - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - immunologiset lääkkeet - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Finnland - finnska - Fimea (Suomen lääkevirasto)

dechra regulatory b.v. - trilostane - kapseli, kova - 5 mg - trilostaani

Evrópusambandið - finnska - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - eturauhasen kasvaimet, kastraatio-resistentin - terapeuttiset radiofarmaseuttiset valmisteet - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Finnland - finnska - Fimea (Suomen lääkevirasto)

macure healthcare limited - lorazepam - tabletti - 2.5 mg - loratsepaami